Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.
Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.